Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17625378 | 0.89 | EPHX1 (0.46) | EPHX1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL14743649 | 0.87 | ARG1 (0.47) | EPHX1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL14743650 | 0.87 | ARG1 (0.47) | EPHX1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL18851527 | 0.86 | EPHX1 (0.43) | EPHX1TSHRALDH1A1CACNA1HDRD2 | |
| SCHEMBL28316678 | 0.83 | HRH3 (0.51) | EPHX1TSHRMEN1KMT2ACACNA1H | |
| SCHEMBL29760194 | 0.83 | HRH3 (0.51) | EPHX1TSHRMEN1KMT2ACACNA1H | |
| SCHEMBL29759987 | 0.83 | HRH3 (0.51) | EPHX1TSHRMEN1KMT2ACACNA1H | |
| SCHEMBL24619420 | 0.83 | TDP1 (0.49) | EPHX1MEN1KMT2AHSD17B10DRD2 | |
| SCHEMBL24619422 | 0.83 | TDP1 (0.49) | EPHX1MEN1KMT2AHSD17B10DRD2 | |
| SCHEMBL18851365 | 0.81 | EPHX1 (0.46) | EPHX1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015445-B1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | PROCTER & GAMBLE (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7482454-B2 | Antimicrobial quinolones, their compositions, and uses | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060100436-A1 | Antimicrobial quinolones, their compositions, and uses | WARNER CHILCOTT COMPANY, LLC | 2006-05-11 | — | — | US | disclosed |
| US-6329391-B1 | ANTIBIOTICS, BACTERICIDES USING QUINOLONES | THE PROCTER & GAMBLE CO. | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100436-A1 | Antimicrobial quinolones, their compositions, and uses | Q6ZSR9, RECQL, QARS1 | EPHX1 956/4885TSHR 1826/4885MEN1 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.